文献速递运动医学关节外科

重组人生长激素预防前交叉韧带重建术后肌肉无力的随机安慰剂对照预试验

The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction: A Pilot, Randomized Placebo-Controlled Trial.
PubMed 文献 · Am J Sports Med · 2020-05-26

这项随机安慰剂对照预试验纳入19例18-35岁男性前交叉韧带重建患者,围手术期给予重组人生长激素或安慰剂6周。结果显示生长激素使股四头肌等速伸膝峰值力矩标准化值较安慰剂组提高29%,并降低MMP3水平36%,但肌肉体积与患者报告结局未见改变。

要点

  • 围手术期6周生长激素治疗可改善前交叉韧带重建术后股四头肌力量。
  • 生长激素组MMP3较安慰剂组低36%,提示可能减少软骨降解。
  • 肌肉体积与患者报告结局评分未见组间差异。

核心结论

  • 生长激素改善了前交叉韧带重建患者的股四头肌力量并降低了MMP3水平。
  • 基于该预试验,值得进一步开展试验评估生长激素改善肌肉功能及潜在保护软骨的能力。

研究设计与样本

  • 随机对照试验,证据等级2级。
  • 共19例18-35岁男性前交叉韧带重建患者随机分为安慰剂组(n=9)与生长激素组(n=10)。
  • 术前1周开始每日两次安慰剂或生长激素治疗,持续至术后5周。
  • 术后6个月内多个时间点测量膝关节肌力与体积、患者报告结局评分及循环生物标志物。
  • 采用混合效应模型评估组间与时间点差异,预试验显著性设定为P<.10,并计算Cohen d效应量。

主要发现

  • 生长激素耐受良好,两组不良事件无差异。
  • 治疗期间生长激素组循环胰岛素样生长因子1增加2.1倍(P<.05;d=2.93)。
  • 主要结局指标为伸膝力量,生长激素组标准化等速伸膝峰值力矩较安慰剂组提高29%(P=.05;d=0.80)。
  • 作为软骨降解间接生物标志物的MMP3在生长激素组低36%(P=.05;d=-1.34)。
  • 生长激素与肌肉体积或患者报告结局评分的变化未见关联。

关键数值与推荐

  • 主要结局为伸膝力量,生长激素组标准化等速伸膝峰值力矩较安慰剂组提高29%(P=.05;d=0.80)。
  • 生长激素组循环胰岛素样生长因子1在治疗期间增加2.1倍(P<.05;d=2.93)。
  • 生长激素组MMP3较安慰剂组低36%(P=.05;d=-1.34)。
  • 预试验显著性阈值设定为P<.10。

临床怎么用

  • 该预试验提示围手术期生长激素可能有助于改善前交叉韧带重建术后股四头肌力量。
  • 生长激素对肌肉体积和患者报告结局未见改善,临床决策需结合进一步试验结果。
  • MMP3降低提示生长激素可能具有潜在软骨保护作用,但需更多研究验证。

局限性

  • 本研究为预试验,样本量小(共19例男性患者)。
  • 显著性阈值设定为P<.10。
  • 仅纳入18-35岁男性患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anterior cruciate ligament (ACL) tears are common knee injuries. Despite undergoing extensive rehabilitation after ACL reconstruction (ACLR), many patients have persistent quadriceps muscle weakness that limits their successful return to play and are also at an increased risk of developing knee osteoarthritis (OA). Human growth hormone (HGH) has been shown to prevent muscle atrophy and weakness in various models of disuse and disease but has not been evaluated in patients undergoing ACLR. HYPOTHESIS: Compared with placebo treatment, a 6-week perioperative treatment course of HGH would protect against muscle atrophy and weakness in patients undergoing ACLR. STUDY DESIGN: Randomized controlled trial; Level of evidence, 2. METHODS: A total of 19 male patients (aged 18-35 years) scheduled to undergo ACLR were randomly assigned to the placebo (n = 9) or HGH (n = 10) group. Patients began placebo or HGH treatment twice daily 1 week before surgery and continued through 5 weeks after surgery. Knee muscle strength and volume, patient-reported outcome scores, and circulating biomarkers were measured at several time points through 6 months after surgery. Mixed-effects models were used to evaluate differences between treatment groups and time points, and as this was a pilot study, significance was set at P < .10. The Cohen d was calculated to determine the effect size. RESULTS: HGH was well-tolerated, and no differences in adverse events between the groups were observed. The HGH group had a 2.1-fold increase in circulating insulin-like growth factor 1 over the course of the treatment period (P < .05; d = 2.93). The primary outcome measure was knee extension strength, and HGH treatment increased normalized peak isokinetic knee extension torque by 29% compared with the placebo group (P = .05; d = 0.80). Matrix metalloproteinase-3 (MMP3), which was used as an indirect biomarker of cartilage degradation, was 36% lower in the HGH group (P = .05; d = -1.34). HGH did not appear to be associated with changes in muscle volume or patient-reported outcome scores. CONCLUSION: HGH improved quadriceps strength and reduced MMP3 levels in patients undergoing ACLR. On the basis of this pilot study, further trials to more comprehensively evaluate the ability of HGH to improve muscle function and potentially protect against OA in patients undergoing ACLR are warranted. REGISTRATION: NCT02420353 ( ClinicalTrials.gov identifier).

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Mendias CL, Enselman ERS, Olszewski AM, et al. The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction: A Pilot, Randomized Placebo-Controlled Trial. Am J Sports Med. 2020. PMID: 32452208. doi:10.1177/0363546520920591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。